- Home
- LGCY vs CRBP Comparison
LGCY vs CRBP Comparison
Compare LGCY & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCY
- CRBP
- Stock Information
- Founded
- LGCY 2009
- CRBP 2009
- Country
- LGCY United States
- CRBP United States
- Employees
- LGCY N/A
- CRBP N/A
- Industry
- LGCY
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- LGCY
- CRBP Health Care
- Exchange
- LGCY NYSE
- CRBP Nasdaq
- Market Cap
- LGCY 117.7M
- CRBP 96.5M
- IPO Year
- LGCY 2024
- CRBP N/A
- Fundamental
- Price
- LGCY $10.86
- CRBP $7.71
- Analyst Decision
- LGCY Strong Buy
- CRBP Strong Buy
- Analyst Count
- LGCY 2
- CRBP 10
- Target Price
- LGCY $10.65
- CRBP $53.56
- AVG Volume (30 Days)
- LGCY 105.8K
- CRBP 219.0K
- Earning Date
- LGCY 05-15-2025
- CRBP 08-05-2025
- Dividend Yield
- LGCY N/A
- CRBP N/A
- EPS Growth
- LGCY 21.53
- CRBP N/A
- EPS
- LGCY 0.62
- CRBP N/A
- Revenue
- LGCY $58,970,210.00
- CRBP N/A
- Revenue This Year
- LGCY $33.77
- CRBP N/A
- Revenue Next Year
- LGCY $24.88
- CRBP $150.03
- P/E Ratio
- LGCY $17.45
- CRBP N/A
- Revenue Growth
- LGCY 37.92
- CRBP N/A
- 52 Week Low
- LGCY $3.60
- CRBP $4.64
- 52 Week High
- LGCY $12.14
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- LGCY N/A
- CRBP 47.66
- Support Level
- LGCY N/A
- CRBP $6.72
- Resistance Level
- LGCY N/A
- CRBP $8.71
- Average True Range (ATR)
- LGCY 0.00
- CRBP 0.53
- MACD
- LGCY 0.00
- CRBP -0.15
- Stochastic Oscillator
- LGCY 0.00
- CRBP 40.66
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.